化療引起的周邊神經病變（CIPN）：市場展望、流行病學、競爭格局、市場預測報告（2025-2035）

市場概覽

• 德國市場預計將從約 1.7 億美元成長到約 2.9 億美元（年複合成長率約 5-6%）。
• 推動這一成長的動力是對支持性護理的需求和未被滿足的需求，目前還沒有核准的預防性療法。

化療引起的周邊神經病變（CIPN）概述

化療引起的周邊神經病變（CIPN）是一種常見的、通常是劑量限制性的毒性反應，與神經毒性抗癌藥物有關，特別是紫杉烷類、含鉑類藥物和長春花生物鹼類藥物。它是由周圍神經系統的多因素損傷引起的，包括軸突變性、粒線體功能障礙以及背根神經節的直接損傷，背根神經節由於其高代謝活性和血神經屏障滲透性而高度易感。

臨床上，化療誘發周邊神經病變（CIPN）表現為對稱性感覺神經病變，呈現「手套襪套樣」分佈，其特徵為麻木、刺痛（感覺異常）和灼痛。一個顯著的特徵是「症狀持續加重」現象，即使停止化療後症狀仍會繼續惡化。

危險因子包括藥物累積暴露、高齡、糖尿病等合併症。目前尚無核准的預防性治療方法，治療僅限於症狀治療。Duloxetine（SNRI）是唯一有實證醫學證據支持的藥物治療選擇，但嚴重的神經病變通常需要減重或停止化療，影響癌症治療效果。

主要亮點

• CIPN 是一種常見的劑量限制性毒性，會影響癌症治療和患者的生活品質。
• 美國（替代人口）的癌症病例數預計將從約 174 萬例增加到約 183 萬例（年均複合成長率約 0.5%）。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• Tarian Pharma
• Ono Pharmaceutical Co. Ltd
• Akeso
• Qilu Pharmaceutical Co., Ltd.
• VM Therapeutics LLC
• Dogwood Therapeutics Inc.

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者人數
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 主要治療方法概述及KOL洞察
• 新興治療方法
  • 重點
  • 值得關注的後期新治療方法－概述、市場上市預期及KOL洞察
  • 值得關注的早期研發管線

第6章：未滿足的需求與TPP分析

• 主要未滿足的需求以及透過新興治療方法實現的未來可能性
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Market Outlook

Thelansis's "Chemotherapy-Induced Peripheral Neuropathy (CIPN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chemotherapy-Induced Peripheral Neuropathy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Chemotherapy-Induced Peripheral Neuropathy (CIPN) Overview

Chemotherapy-induced peripheral neuropathy (CIPN) is a prevalent and often dose-limiting toxicity associated with neurotoxic anticancer agents, particularly taxanes, platinum compounds, and vinca alkaloids. It arises from multifactorial damage to the peripheral nervous system, including axonal degeneration, mitochondrial dysfunction, and direct injury to dorsal root ganglia, which are highly susceptible due to their metabolic activity and permeable blood-nerve barrier.

Clinically, CIPN presents as a symmetric sensory neuropathy in a "glove-and-stocking" distribution, characterized by numbness, tingling (paresthesia), and burning pain. A notable feature is the "coasting" phenomenon, where symptoms continue to worsen even after cessation of chemotherapy.

Risk factors include cumulative drug exposure, advanced age, and comorbidities such as diabetes. Currently, there are no approved therapies for prevention, and management remains symptomatic. Duloxetine (SNRI) is the only evidence-based pharmacologic option, while severe neuropathy often necessitates dose reduction or discontinuation of chemotherapy, impacting cancer treatment outcomes.

Key Highlights

• CIPN is a common, dose-limiting toxicity impacting cancer treatment and patient quality of life
• US cancer incidence (proxy population) expected to grow from ~1.74M to ~1.83M (~0.5% CAGR)

Market Overview

• Germany market projected to grow from ~$170M to ~$290M (~5-6% CAGR)
• Growth driven by supportive care demand and unmet need, with no approved preventive therapies

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

• Tarian Pharma
• Ono Pharmaceutical Co. Ltd
• Akeso
• Qilu Pharmaceutical Co., Ltd.
• VM Therapeutics LLC
• Dogwood Therapeutics Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)